GlassScriptPhysician profile
Jeanne Davis
NPI 1619477171
$18,528.84
in general payments reported to CMS, 2019-2025
36 companies · $4,116 in 2025
The $4,116 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $948 · 2022: $3,266 · 2023: $4,411 · 2024: $5,788 · 2025: $4,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,200 · Travel and Lodging: $382 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,569.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,200.00 |
| Travel and Lodging | $381.69 |
| Education | $163.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $3,918.88 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $2,154.70 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Abbvie INC. | $1,901.51 | 2021-2025 | |
| Axsome Therapeutics, INC. | $1,692.37 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $1,286.14 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,180.12 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $791.81 | 2022-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $633.59 | 2021-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $553.87 | 2021-2025 | Caplyta |
| Boston Scientific Corporation | $471.90 | 2024-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $451.93 | 2023-2025 | |
| Novo Nordisk INC | $391.83 | 2022-2025 | Wegovy |
| Idorsia Pharmaceuticals US INC | $362.65 | 2023-2025 | Quviviq, Quviviq |
| Corium, LLC | $293.67 | 2022-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $245.47 | 2024-2025 | Cobenfy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $244.86 | 2021-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $191.85 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $176.68 | 2022-2023 | |
| Bausch Health US, LLC | $136.00 | 2022-2025 | Aplenzin, Wellbutrin |
| Alexion Pharmaceuticals, INC. | $131.08 | 2025 | |
| Ucb, INC. | $127.92 | 2025 | Rystiggo |
| Viatris Specialty LLC | $125.00 | 2025 | Yupelri |
| Abiomed | $124.96 | 2024 | Impella |
| Astellas Pharma US INC | $124.65 | 2024 | Veozah |
| Ultragenyx Pharmaceutical INC. | $121.92 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.63 | 2021-2023 | Trintellix |
| Neurelis, INC. | $120.65 | 2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $115.19 | 2021-2022 | |
| Eisai INC. | $83.40 | 2025 | |
| Supernus Pharmaceuticals, INC. | $47.70 | 2021 | |
| Ironshore Pharmaceuticals INC. | $47.50 | 2022-2023 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $41.70 | 2025 | Jornay Pm |
| Indivior INC. | $39.94 | 2021-2023 | Sublocade |
| Avanir Pharmaceuticals, INC. | $32.61 | 2022 | |
| Janssen Biotech, INC. | $22.47 | 2024 | Spravato |
| Lilly USA, LLC | $20.69 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanne Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.